Abivax stock soars after new data on bowel disease medicine
Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease, clawing back heavy losses from earlier in the month when the same trial had investors questioning the drug’s future. Abivax stock was last trading up 34% at 111.7 euros. The move comes after it crashed…
